|
1) 半田 誠. コラーゲン受容体異常症. α2β1インテグリン欠損症. 血栓止血誌. 2005; 162: 195-9
|
|
|
|
|
2) 諸井将明. コラーゲン受容体異常症: GPVI欠損症. 血栓止血誌. 2005; 162: 187-94
|
|
|
|
|
|
3) Sachs UJ, Nieswandt B. In vivo thrombus formation in murine models. Circ Res. 2007; 100: 979-91
|
|
|
|
|
4) Noris P, Guidetti GF, Conti V, et al. Autosomal dominant thrombocytopenias with reduced expression of glycoprotein Ia. Thromb Haemost. 2006; 95: 483-9
|
|
|
|
|
|
5) Bellucci S, Huisse MG, Boval B, et al. Defective collagen-induced platelet activation in two patients with malignant haemopathies is related to a defect in the GPVI-coupled signalling pathway. Thrombosis and Haemostasis. 2005; 93: 130-8
|
|
|
|
|
|
6) Dunkley S, Arthur JF, Evans S, et al. A familial platelet function disorder associated with abnormal signalling through the glycoprotein VI pathway. Br J Haematol. 2007; 137: 569-77
|
|
|
|
|
|
7) Kojima H, Moroi M, Jung SM, et al. Characterization of a patient with glycoprotein (GP) VI deficiency possessing neither anti-GPVI autoantibody nor genetic aberration. J Thromb Haemost. 2006; 4: 2433-42
|
|
|
|
|
|
8) Andrews RK, Karunakaran D, Gardiner EE, et al. Platelet receptor proteolysis: a mechanism for downregulating platelet reactivity. Arterioscler Thromb Vasc Biol. 2007; 27: 1511-20
|
|
|
|
|
|
9) Stephens G, Yan Y, Jandrot-Perrus M, et al. Platelet activation induces metalloproteinase-dependent GP VI cleavage to down-regulate platelet reactivity to collagen. Blood. 2005; 105: 186-91
|
|
|
|
|
|
10) Gardiner EE, Karunakaran D, Shen Y, et al. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost. 2007; 5: 1530-7
|
|
|
|
|
|
11) Boylan B, Berndt MC, Kahn ML, et al. Activation-independent, antibody-mediated removal of GPVI from circulating human platelets: development of a novel NOD/SCID mouse model to evaluate the in vivo effectiveness of anti-human platelet agents. Blood. 2006; 108: 908-14
|
|
|
|
|
|
12) Rabie T, Varga-Szabo D, Bender M, et al. Diverging signaling events control the pathway of GPVI down-regulation in vivo. Blood. 2007; 110: 529-35
|
|
|
|
|
|
13) Mangin P, Yap CL, Nonne C, et al. Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRgamma deficiency. Blood. 2006; 107: 4346-53
|
|
|
|
|
|
14) Dubois C, Panicot-Dubois L, Gainor JF, et al. Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest. 2007; 117: 953-60
|
|
|
|
|
|
15) Dubois C, Panicot-Dubois L, Merrill-Skoloff G, et al. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood. 2006; 107: 3902-6
|
|
|
|
|
|
16) Penz S, Reininger AJ, Brandl R, et al. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. FASEB J. 2005; 19: 898-909
|
|
|
|
|
|
17) Kleinschnitz C, Pozgajova M, Pham M, et al. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007; 115: 2323-30
|
|
|
|
|
|
18) Horii K, Kahn ML, Herr AB. Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. Blood. 2006; 108: 936-42
|
|
|
|
|
|
19) Kasirer-Friede A, Kahn ML, Shattil SJ. Platelet integrins and immunoreceptors. Immunol Rev. 2007; 218: 247-64
|
|
|
|
|